LOXL2
Overview
LOXL2 (Lysyl Oxidase Like 2) is a member of the lysyl oxidase family of amine oxidases involved in extracellular matrix remodeling and epithelial-to-mesenchymal transition (EMT). In cancer, LOXL2 promotes tumor invasion, metastasis, and therapy resistance by crosslinking collagens and enabling mesenchymal transdifferentiation programs.
Alterations observed in the corpus
- LOXL2 is among mesenchymal-transition transcripts up-regulated in anti-PD-1 non-responding pretreatment melanoma tumors; co-enriched within the IPRES (innate anti-PD-1 resistance) transcriptional signature PMID:26997480
Cancer types (linked)
- Melanoma: LOXL2 up-regulation in pretreatment tumors associated with innate resistance to anti-PD-1 immunotherapy PMID:26997480
Co-occurrence and mutual exclusivity
Therapeutic relevance
- LOXL2 up-regulation as part of the IPRES resistance program suggests that targeting EMT/mesenchymal programs may be a strategy to restore anti-PD-1 sensitivity in melanoma PMID:26997480
Open questions
- Whether pharmacological suppression of the IPRES/mesenchymal program (including LOXL2) restores anti-PD-1 sensitivity has not been directly demonstrated PMID:26997480
Sources
This page was processed by crosslinker on 2026-05-14.